Vopratelimab JTX 2011|cas:2039148-04-2|西域试剂

Vopratelimab JTX 2011,95.00%

产品编号：Bellancom-P99382| CAS NO：2039148-04-2

本网站销售的所有产品仅用于工业应用或者科学研究等非医疗目的,不可用于人类或动物的临床诊断或者治疗,非药用,非食用，

货号	包装	价格	库存与货期	购买量	操作
Bellancom-P99382		￥5500.00	杭州北京（现货）
Bellancom-P99382		￥14500.00	杭州北京（现货）

增值税发票√顺丰快递√订货电话：18601927057

Vopratelimab JTX 2011

产品介绍

Vopratelimab (JTX-2011) 是一种人源化免疫球蛋白 G1-kappa 激动剂单克隆抗体，特异性结合到诱导型 T 细胞 CO 刺激因子 (ICOS)。Vopratelimab 保留了物种交叉反应性，对 hICOS 的亲和力为 0.93 nM，对大鼠 ICOS 的亲和力为 3.7 nM，对 mICOS 的亲和力为 0.64 nM。Vopratelimab 具有抗肿瘤免疫反应。

生物活性

Vopratelimab (JTX-2011) is a humanized immunoglobulin G1-kappa agonist monoclonal antibody that pecifically binds to the Inducible CO-Stimulator of T cells (ICOS). Vopratelimab retains species cross-reactivity with affinities of 0.93 nM to hICOS, 0.46 nM to cynomolgus ICOS, 3.7 nM to rat ICOS, and 0.64 nM to mICOS. Vopratelimab has antitumor immune response.

体外研究

Vopratelimab (JTX-2011; 0.001-10 μg/mL; 3 d; CD4 T 细胞) 具有激活原代人 T 细胞的活性，驱动 IFNγ、IL-17a、IL-10、IL-9、GM-CSF、TNFα 和 IL-21 分泌。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

体内研究

Vopratelimab (JTX-2011; 0.25-0.3 mg/kg; i.p.; 每周两次，持续 2 周) 促进 Sa1/N 小鼠同基因肿瘤模型中的肿瘤消退。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female A/J, Balb/c and C57BL/6 mice with Sa1/N murine syngeneic tumor model
Dosage:	0.25-0.3 mg/kg
Administration:	Intraperitoneal injection; twice a week, for 2 weeks
Result:	Regressed tumor and protected long-term in the Sa1/N murine syngeneic tumor model.

体内研究

Vopratelimab (JTX-2011; 0.25-0.3 mg/kg; i.p.; 每周两次，持续 2 周) 促进 Sa1/N 小鼠同基因肿瘤模型中的肿瘤消退。

西域 has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Female A/J, Balb/c and C57BL/6 mice with Sa1/N murine syngeneic tumor model
Dosage:	0.25-0.3 mg/kg
Administration:	Intraperitoneal injection; twice a week, for 2 weeks
Result:	Regressed tumor and protected long-term in the Sa1/N murine syngeneic tumor model.